NCT02931045

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Medical University of Warsaw · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation. Antagonists against the P2Y12 receptor, which are established in secondary prevention of myocardial infarction, have unexplained anti-inflammatory effects. A novel P2Y12 receptor antagonist ticagrelor reduced infection-related mortality compared to clopidogrel, previous standard treatment for patients with myocardial infarction. Activated platelets release pro-inflammatory and procoagulant platelet extracellular vesicles. The investigators assume that decrease in infection-related mortality in patients treated with ticagrelor may be explained by greater inhibition of the release of platelet vesicles by ticagrelor, compared to clopidogrel. This study is expected to identify an additional mechanism of action of ticagrelor, which might contribute to the observed clinical benefits in patients treated with ticagrelor.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Ticagrelor	Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
DRUG	Clopidogrel	Comparison of clopidogrel with another antiplatelet drug (ticagrelor)

Timeline

• Start date: 2017-12-30
• Primary completion: 2018-12-30
• Completion: 2019-12-30
• First posted: 2016-10-12
• Last updated: 2020-12-23
• Results posted: 2020-12-23

Locations

2 sites across 2 countries: Netherlands, Poland